APP and amyloidosis: Taken together, the present study provides preclinical evidence that inhibition of JNK3 phosphorylation by PBM treatment can effectively rescue AMPA receptor endocytosis and dramatically reduce amyloid load, neuroinflammation, and synaptic loss in APP/PS1 transgenic mice.